Inflammation Research

, Volume 67, Issue 5, pp 455–466 | Cite as

The peptide lycosin-I attenuates TNF-α-induced inflammation in human umbilical vein endothelial cells via IκB/NF-κB signaling pathway

  • Xianyao Li
  • Yaqin Tang
  • Binbin Ma
  • Zheng Wang
  • Jinying Jiang
  • Shengjie Hou
  • Shuhang Wang
  • Jie Zhang
  • Meichun Deng
  • Zhigui Duan
  • Xing Tang
  • Alex F. Chen
  • Liping Jiang
Original Research Paper
  • 110 Downloads

Abstract

Objective

The peptide lycosin-I has anti-bacterial and anti-cancer capacities. However, the anti-inflammatory activity of lycosin-I remains unknown. We investigated whether lycosin-I could attenuate inflammation.

Materials and methods

Human umbilical vein endothelial cells (HUVECs) were treated with lycosin-I before exposure to tumor necrosis factor-α (TNF-α). The expression of intercellular cell adhesion molecule-1 (ICAM-1), nuclear transcription factor-kappa B (NF-κB) p65 and inhibitory subunit of NF-κB alpha (IκBα) was evaluated by western blot. The expression of interleukin-6 (IL-6) and interleukin-8 (IL-8) was detected by quantitative RT-PCR or ELISA. Immunofluorescence analysis was used to determine the impact of lycosin-I on NF-κB pathway. C57BL/6 mice were pretreated with lycosin-I before exposure with lipopolysaccharide (LPS).

Results

Lycosin-I significantly reduced the TNF-α-enhanced expression of IL-6, IL-8 and ICAM-1. Lycosin-I also inhibited the human monocyte cells adhesion to HUVECs. We further demonstrated that lycosin-I could effectively suppress the reaction of endothelial cells to TNF-α by inhibiting IκBα degradation. Subsequently, the phosphorylation and translocation of NF-κB p65 could also be attenuated. Furthermore, lycosin-I exhibited a significant protection of C57BL/6 mice against LPS-induced death.

Conclusions

Our results suggested that the anti-inflammatory activity of lycosin-I was associated with NF-κB activation and lycosin-I had potential to be a novel therapeutic candidate for inflammatory diseases.

Keywords

Lycosin-I Inflammation HUVECs NF-κB 

Notes

Acknowledgements

This project was supported by the Natural Science Foundation of Hunan Province (2015JJ2192 and 2017JJ2372), China Postdoctoral Science Foundation (2015M580704), Scientific Research Foundation of Central South University (2014JSJJ027), the National Natural Science Foundation of China (30901874 and 31672290) and National Undergraduate Innovation Training Program of Central South University (201510533321 and 201610533535). The authors are grateful to Dr. Songping, Liang and Zhonghua Liu, Hunan Normal University, for providing professional advice.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

References

  1. 1.
    Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115 – 26.  https://doi.org/10.1056/nejm199901143400207.CrossRefPubMedGoogle Scholar
  2. 2.
    Manduteanu I, Simionescu M. Inflammation in atherosclerosis: a cause or a result of vascular disorders? J Cell Mol Med. 2012;16(9):1978–90.  https://doi.org/10.1111/j.1582-4934.2012.01552.x.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Libby P. Inflammation in atherosclerosis. arteriosclerosis, thrombosis, and vascular biology. 2012;32(9):2045–51.  https://doi.org/10.1161/atvbaha.108.179705.
  4. 4.
    Yu BL, Wang SH, Peng DQ, Zhao SP. HDL and immunomodulation: an emerging role of HDL against atherosclerosis. Immunol Cell Biol. 2010;88(3):285–90.  https://doi.org/10.1038/icb.2009.112.CrossRefPubMedGoogle Scholar
  5. 5.
    Kinlay S, Ganz P. Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am J Cardiol. 1997;80(9A):11I-6I.Google Scholar
  6. 6.
    Old LJ. Tumor necrosis factor (TNF). Science. 1985;230(4726):630–2.CrossRefPubMedGoogle Scholar
  7. 7.
    Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology. 2005;115(1):1–20.  https://doi.org/10.1111/j.1365-2567.2005.02143.x.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov. 2013;12(2):147–68.  https://doi.org/10.1038/nrd3930.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chai H, Wang Q, Huang L, Xie T, Fu Y. Ginsenoside Rb1 inhibits tumor necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Biol Pharm Bull. 2008;31(11):2050–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Chang CC, Chu CF, Wang CN, Wu HT, Bi KW, Pang JH, et al. The anti-atherosclerotic effect of tanshinone IIA is associated with the inhibition of TNF-alpha-induced VCAM-1, ICAM-1 and CX3CL1 expression. Phytomed: Int J Phytother Phytopharmacol. 2014;21(3):207 – 16.  https://doi.org/10.1016/j.phymed.2013.09.012.CrossRefGoogle Scholar
  11. 11.
    Sengul S, Zwizinski C, Batuman V. Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am J Physiol Renal Physiol. 2003;284(6):F1245-54.  https://doi.org/10.1152/ajprenal.00350.2002.CrossRefPubMedGoogle Scholar
  12. 12.
    de Haij S, Bakker AC, van der Geest RN, Haegeman G, Vanden Berghe W, Aarbiou J, et al. NF-kappaB mediated IL-6 production by renal epithelial cells is regulated by c-jun NH2-terminal kinase. J Am Soc Nephrol: JASN. 2005;16(6):1603–11.  https://doi.org/10.1681/asn.2004090781.CrossRefPubMedGoogle Scholar
  13. 13.
    Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Investig. 1998;101(2):353–63.  https://doi.org/10.1172/jci1195.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999;398(6729):718–23.  https://doi.org/10.1038/19546.CrossRefPubMedGoogle Scholar
  15. 15.
    Fenyo IM, Gafencu AV. The involvement of the monocytes/macrophages in chronic inflammation associated with atherosclerosis. Immunobiology. 2013;218(11):1376–84.  https://doi.org/10.1016/j.imbio.2013.06.005.CrossRefPubMedGoogle Scholar
  16. 16.
    Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13(10):709–21.  https://doi.org/10.1038/nri3520.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Ann Rev Immunol. 1994;12:141–79.  https://doi.org/10.1146/annurev.iy.12.040194.001041.CrossRefGoogle Scholar
  18. 18.
    Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J. 1995;9(10):899–909.CrossRefPubMedGoogle Scholar
  19. 19.
    Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harbor Perspect Biol. 2012;4(3).  https://doi.org/10.1101/cshperspect.a006049.
  20. 20.
    Morris-Rosenfeld S, Lipinski MJ, McNamara CA. Understanding the role of B cells in atherosclerosis: potential clinical implications. Expert Rev Clin Immunol. 2014;10(1):77–89.  https://doi.org/10.1586/1744666x.2014.857602.CrossRefPubMedGoogle Scholar
  21. 21.
    Kondkar AA, Abu-Amero KK. Utility of circulating microRNAs as clinical biomarkers for cardiovascular diseases. BioMed Res Int. 2015;2015:821823.  https://doi.org/10.1155/2015/821823.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Lee SW, Kim HC, Lee HS, Suh I. Erratum to: thirty-year trends in mortality from cardiovascular diseases in Korea. Korean Circ J. 2015;45(5):442.  https://doi.org/10.4070/kcj.2015.45.5.442.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Abubakar II, Tillmann T, Banerjee A. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71.  https://doi.org/10.1016/s0140-6736(14)61682-2.CrossRefGoogle Scholar
  24. 24.
    Skarnes RC, Watson DW. Antimicrobial factors of normal tissues and fluids. Bacteriol Rev. 1957;21(4):273–94.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Epand RM, Vogel HJ. Diversity of antimicrobial peptides and their mechanisms of action. Biochimica et biophysica acta. 1999;1462(1–2):11–28.CrossRefPubMedGoogle Scholar
  26. 26.
    Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005;3(3):238–50.  https://doi.org/10.1038/nrmicro1098.CrossRefPubMedGoogle Scholar
  27. 27.
    Wang L, Wang YJ, Liu YY, Li H, Guo LX, Liu ZH, et al. In vitro potential of Lycosin-I as an alternative antimicrobial drug for treatment of multidrug-resistant Acinetobacter baumannii infections. Antimicrobial Agents Chemother. 2014;58(11):6999–7002.  https://doi.org/10.1128/AAC.03279-14.CrossRefGoogle Scholar
  28. 28.
    Huang L, Tang Y, Qin J, Peng Y, Yuan Q, Zhang F, et al. Vasoactive intestinal peptide enhances TNF-alpha-induced IL-6 and IL-8 synthesis in human proximal renal tubular epithelial cells by NF-kappaB-dependent mechanism. Inflammation. 2012;35(3):1154–60.  https://doi.org/10.1007/s10753-011-9423-4.CrossRefPubMedGoogle Scholar
  29. 29.
    Zhang Z, Mu L, Tang J, Duan Z, Wang F, Wei L, et al. A small peptide with therapeutic potential for inflammatory acne vulgaris. PLoS One. 2013;8(8):e72923.  https://doi.org/10.1371/journal.pone.0072923.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Fontes JA, Rose NR, Cihakova D. The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine. 2015;74(1):62–8.  https://doi.org/10.1016/j.cyto.2014.12.024.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Feng M, Shu Y, Yang Y, Zheng X, Li R, Wang Y, et al. Ulinastatin attenuates experimental autoimmune encephalomyelitis by enhancing anti-inflammatory responses. Neurochem Int. 2014;64:64–72.  https://doi.org/10.1016/j.neuint.2013.11.007.CrossRefPubMedGoogle Scholar
  32. 32.
    Rao RM, Yang L, Garcia-Cardena G, Luscinskas FW. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circulation research. 2007;101(3):234–47.  https://doi.org/10.1161/CIRCRESAHA.107.151860b.CrossRefPubMedGoogle Scholar
  33. 33.
    Wang B, Wei H, Prabhu L, Zhao W, Martin M, Hartley AV, et al. Role of novel serine 316 phosphorylation of the p65 subunit of NF-kappaB in differential gene regulation. J Biol Chem. 2015;290(33):20336–47.  https://doi.org/10.1074/jbc.M115.639849.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci. 2005;30(1):43–52.  https://doi.org/10.1016/j.tibs.2004.11.009.CrossRefPubMedGoogle Scholar
  35. 35.
    Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336(15):1066–71.  https://doi.org/10.1056/nejm199704103361506.CrossRefPubMedGoogle Scholar
  36. 36.
    Brown JD, Lin CY, Duan Q, Griffin G, Federation AJ, Paranal RM, et al. NF-kappaB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol Cell. 2014;56(2):219–31.  https://doi.org/10.1016/j.molcel.2014.08.024.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Mako V, Czucz J, Weiszhar Z, Herczenik E, Matko J, Prohaszka Z, et al. Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL-1beta, TNF-alpha, and LPS. Cytometry Part A J Int Soc Anal Cytol. 2010;77(10):962–70.  https://doi.org/10.1002/cyto.a.20952.CrossRefGoogle Scholar
  38. 38.
    Chistiakov DA, Sobenin IA, Orekhov AN. Regulatory T cells in atherosclerosis and strategies to induce the endogenous atheroprotective immune response. Immunol Lett. 2013;151(1–2):10–22.  https://doi.org/10.1016/j.imlet.2013.01.014.CrossRefPubMedGoogle Scholar
  39. 39.
    Coumbe AG, Pritzker MR, Duprez DA. Cardiovascular risk and psoriasis: beyond the traditional risk factors. Am J Med. 2014;127(1):12–8.  https://doi.org/10.1016/j.amjmed.2013.08.013.CrossRefPubMedGoogle Scholar
  40. 40.
    Khalil RA. Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease. Biochem Pharmacol. 2013;86(12):1627–42.  https://doi.org/10.1016/j.bcp.2013.09.024.CrossRefPubMedGoogle Scholar
  41. 41.
    Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002;2(10):725–34.  https://doi.org/10.1038/nri910.CrossRefPubMedGoogle Scholar
  42. 42.
    Fu Y, Wei Z, Zhou E, Zhang N, Yang Z. Cyanidin-3-O-beta-glucoside inhibits lipopolysaccharide-induced inflammatory response in mouse mastitis model. J Lipid Res. 2014;55(6):1111–9.  https://doi.org/10.1194/jlr.M047340.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Ding Y, Liao W, He X, Xiang W, Lu Q. CSTMP exerts anti-inflammatory effects on LPS-induced human renal proximal tubular epithelial cells by inhibiting TLR4-mediated NF-kappaB pathways. Inflammation. 2016;39(2):849–59.  https://doi.org/10.1007/s10753-016-0315-5.CrossRefPubMedGoogle Scholar
  44. 44.
    Ledebur HC, Parks TP. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers. J Biol Chem. 1995;270(2):933–43.CrossRefPubMedGoogle Scholar
  45. 45.
    Lockyer JM, Colladay JS, Alperin-Lea WL, Hammond T, Buda AJ. Inhibition of nuclear factor-kappaB-mediated adhesion molecule expression in human endothelial cells. Circul Res. 1998;82(3):314–20.CrossRefGoogle Scholar
  46. 46.
    Wang L, Xu Y, Yu Q, Sun Q, Gu Q, Xu X. H-RN, a novel antiangiogenic peptide derived from hepatocyte growth factor inhibits inflammation in vitro and in vivo through PI3K/AKT/IKK/NF-kappaB signal pathway. Biochem Pharmacol. 2014;89(2):255–65.  https://doi.org/10.1016/j.bcp.2014.02.026.CrossRefPubMedGoogle Scholar
  47. 47.
    Wan M, Liu J, Ouyang X. Nucleotide-binding oligomerization domain 1 regulates Porphyromonas gingivalis-induced vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 expression in endothelial cells through NF-kappaB pathway. J Periodontal Res. 2015;50(2):189–96.  https://doi.org/10.1111/jre.12192.CrossRefPubMedGoogle Scholar
  48. 48.
    Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Investig. 2001;107(3):255–64.  https://doi.org/10.1172/jci10373.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Brasier AR. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res. 2010;86(2):211–8.  https://doi.org/10.1093/cvr/cvq076.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Kurokouchi K, Kambe F, Kikumori T, Sakai T, Sarkar D, Ishiguro N, et al. Effects of glucocorticoids on tumor necrosis factor alpha-dependent activation of nuclear factor kappaB and expression of the intercellular adhesion molecule 1 gene in osteoblast-like ROS17/2.8 cells. J Bone Miner Res. 2000;15(9):1707–15.  https://doi.org/10.1359/jbmr.2000.15.9.1707.CrossRefPubMedGoogle Scholar
  51. 51.
    Eberhardt W, Schulze M, Engels C, Klasmeier E, Pfeilschifter J. Glucocorticoid-mediated suppression of cytokine-induced matrix metalloproteinase-9 expression in rat mesangial cells: involvement of nuclear factor-kappaB and Ets transcription factors. Mol Endocrinol (Baltimore. Md). 2002;16(8):1752–66.  https://doi.org/10.1210/me.2001-0278.CrossRefGoogle Scholar
  52. 52.
    Vital AL, Goncalo M, Cruz MT, Figueiredo A, Duarte CB, Lopes MC. Dexamethasone prevents granulocyte-macrophage colony-stimulating factor-induced nuclear factor-kappaB activation, inducible nitric oxide synthase expression and nitric oxide production in a skin dendritic cell line. Mediators Inflammation. 2003;12(2):71–8.  https://doi.org/10.1080/0962935031000097673.CrossRefGoogle Scholar
  53. 53.
    Ma W, Gee K, Lim W, Chambers K, Angel JB, Kozlowski M, et al. Dexamethasone inhibits IL-12p40 production in lipopolysaccharide-stimulated human monocytic cells by down-regulating the activity of c-Jun N-terminal kinase, the activation protein-1, and NF-kappa B transcription factors. J Immunol (Baltimore: 1950). 2004;172(1):318–30.Google Scholar
  54. 54.
    Mattioli I, Sebald A, Bucher C, Charles RP, Nakano H, Doi T, et al. Transient and selective NF-kappa B p65 serine 536 phosphorylation induced by T cell costimulation is mediated by I kappa B kinase beta and controls the kinetics of p65 nuclear import. J Immunol (Baltimore: 1950). 2004;172(10):6336–44.Google Scholar
  55. 55.
    Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD, et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2015;372(14):1301–11.  https://doi.org/10.1056/NEJMoa1500896.CrossRefPubMedGoogle Scholar
  56. 56.
    Luan YY, Dong N, Xie M, Xiao XZ, Yao YM. The significance and regulatory mechanisms of innate immune cells in the development of sepsis. J Interferon Cytokine Res. 2014;34(1):2–15.  https://doi.org/10.1089/jir.2013.0042.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Luan YY, Yao YM, Xiao XZ, Sheng ZY. Insights into the apoptotic death of immune cells in sepsis. J Interferon Cytokine Res. 2015;35(1):17–22.  https://doi.org/10.1089/jir.2014.0069.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Xianyao Li
    • 1
  • Yaqin Tang
    • 1
  • Binbin Ma
    • 1
  • Zheng Wang
    • 2
  • Jinying Jiang
    • 3
  • Shengjie Hou
    • 1
  • Shuhang Wang
    • 1
  • Jie Zhang
    • 1
  • Meichun Deng
    • 4
  • Zhigui Duan
    • 5
  • Xing Tang
    • 6
  • Alex F. Chen
    • 7
    • 8
  • Liping Jiang
    • 1
    • 7
  1. 1.Department of Parasitology, Xiangya School of MedicineCentral South UniversityChangshaChina
  2. 2.The First Department of General Surgery, the Third Xiangya HospitalCentral South UniversityChangshaChina
  3. 3.Department of NeonatologyHunan Provincial Maternal and Child Health Care HospitalChangshaChina
  4. 4.Department of Biochemistry, School of Life SciencesCentral South UniversityChangshaChina
  5. 5.Key Laboratory of Protein Chemistry and Developmental Biology of the Ministry of Education, College of Life SciencesHunan Normal UniversityChangshaChina
  6. 6.College of Chemistry, Biology, and Material ScienceEast China Institute of TechnologyNanchangChina
  7. 7.Xiangya School of Pharmaceutical SciencesCentral South UniversityChangshaChina
  8. 8.Center for Vascular Disease and Translational MedicineThe Third Xiangya Hospital of Central South UniversityChangshaChina

Personalised recommendations